When considering what names to put on your watch list, focus on stocks with an 80 or higher RS Rating. ACM Research Cl A now meets that criteria, with an increase from 78 to 81 Monday.
IBD's unique rating measures price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the best stocks tend to have an RS Rating of over 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
ACM Research Cl A is building a cup without handle with a 26.32 buy point. See if it can break out in volume at least 40% above average. Be aware that it's a third-stage base. Such patterns can work and do sometimes launch nice runs, but they're more likely to fail than earlier-stage consolidations.
The company reported 11% EPS growth in the latest quarterly report, while sales growth came in at 21%. The next quarterly numbers are expected on or around Feb. 26.
The company holds the No. 3 rank among its peers in the Electronics-Semiconductor Equipment industry group. Nova is the top-ranked stock within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
